Albert Schilling
About
In The Last Decade
Albert Schilling
25 papers receiving 519 citations
Peers
Comparison fields: 5 of 102
- Oncology 276
- Hematology 205
- Molecular Biology 189
- Pulmonary and Respiratory Medicine 80
- Immunology 59
Countries citing papers authored by Albert Schilling
This map shows the geographic impact of Albert Schilling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Schilling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Schilling more than expected).
Fields of papers citing papers by Albert Schilling
This network shows the impact of papers produced by Albert Schilling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Schilling. The network helps show where Albert Schilling may publish in the future.
Co-authorship network of co-authors of Albert Schilling
This figure shows the co-authorship network connecting the top 25 collaborators of Albert Schilling. A scholar is included among the top collaborators of Albert Schilling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Schilling. Albert Schilling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 4 | |
| 3 | 1 | |
| 4 | Resection of multiple lung metastases--where are the limits? | 7 |
| 5 | 37 | |
| 6 | 26 | |
| 7 | 5 | |
| 8 | 25 | |
| 9 | [Epidemiology of refusal to permit an autopsy]. | 1 |
| 10 | Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma. | 20 |
| 11 | 5 | |
| 12 | Ancillary measures in treatment of myeloma. Use of immune serum globulin, fluoride, or androgen. | 2 |
| 13 | 1 | |
| 14 | 41 | |
| 15 | 67 | |
| 16 | Concurrent combination chemotherapy of human solid tumors: experience with a three-drug regimen and review of the literature. | 31 |
| 17 | Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. | 38 |
| 18 | 7 | |
| 19 | 94 | |
| 20 | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.